Literature DB >> 23179209

[Round robin test for detection of genomic aberrations in non-Hodgkin lymphoma by in situ hybridization].

T F E Barth1, L Floßbach, H-W Bernd, R Bob, M Buck, S B Cogliatti, A C Feller, M L Hansmann, S Hartmann, H Horn, W Klapper, D Kradolfer, T Mattfeldt, P Möller, A Rosenwald, H Stein, C Thorns, G Ott.   

Abstract

BACKGROUND: The detection of characteristic genomic aberrations by fluorescence in situ hybridization (FISH) has a high diagnostic impact on lymphomas according to the World Health Organization (WHO). To investigate the reproducibility of non-isotopic ISH results a multicenter trial was carried out involving eight institutes for hematopathology.
MATERIAL AND METHODS: Analyses were performed on two diffuse large B-cell lymphomas (DLBCL) without known aberrations, on one follicular lymphoma with a IGH/BCL2 translocation and BCL6 split and on two B-cell lymphomas intermediate between DLBCL and Burkitt's lymphoma with c-MYC and BCL2 rearrangements, one with an additional BCL6 split. Break-apart probes for BCL6 and c-MYC, as well as fusion probes for the c-MYC/IGH and the IGH/BCL2 translocations were used.
RESULTS: All aberrations were correctly detected by all centres and no false positive or false negative results were obtained. The numbers of positive cells varied from 25% to 94%. Pearson's correlation coefficient between the centres was always > 0.8.
CONCLUSIONS: The ISH analysis of recurrent genomic aberrations in formalin-fixed paraffin-embedded (FFPE) tissue is a highly reproducible technique which yields substantial additive help for lymphoma diagnostics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23179209     DOI: 10.1007/s00292-012-1719-0

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  14 in total

1.  B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

Authors:  Shaoying Li; Pei Lin; Luis E Fayad; Patrick A Lennon; Roberto N Miranda; C Cameron Yin; E Lin; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2011-10-14       Impact factor: 7.842

2.  Diagnosis of Burkitt lymphoma in due time: a practical approach.

Authors:  Sergio B Cogliatti; Urban Novak; Samuel Henz; Ulrico Schmid; Peter Möller; Thomas F E Barth
Journal:  Br J Haematol       Date:  2006-08       Impact factor: 6.998

3.  Detection by the fluorescence in situ hybridization technique of MYC translocations in paraffin-embedded lymphoma biopsy samples.

Authors:  Eugenia Haralambieva; Alison H Banham; Christian Bastard; Georges Delsol; Philippe Gaulard; German Ott; Stefano Pileri; Jonathan A Fletcher; David Y Mason
Journal:  Br J Haematol       Date:  2003-04       Impact factor: 6.998

Review 4.  FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue.

Authors:  Roland A Ventura; Jose I Martin-Subero; Margaret Jones; Joanna McParland; Stefan Gesk; David Y Mason; Reiner Siebert
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

5.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

Authors:  Michael Hummel; Stefan Bentink; Hilmar Berger; Wolfram Klapper; Swen Wessendorf; Thomas F E Barth; Heinz-Wolfram Bernd; Sergio B Cogliatti; Judith Dierlamm; Alfred C Feller; Martin-Leo Hansmann; Eugenia Haralambieva; Lana Harder; Dirk Hasenclever; Michael Kühn; Dido Lenze; Peter Lichter; Jose Ignacio Martin-Subero; Peter Möller; Hans-Konrad Müller-Hermelink; German Ott; Reza M Parwaresch; Christiane Pott; Andreas Rosenwald; Maciej Rosolowski; Carsten Schwaenen; Benjamin Stürzenhofecker; Monika Szczepanowski; Heiko Trautmann; Hans-Heinrich Wacker; Rainer Spang; Markus Loeffler; Lorenz Trümper; Harald Stein; Reiner Siebert
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

6.  Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.

Authors:  Milena Sant; Claudia Allemani; Carmen Tereanu; Roberta De Angelis; Riccardo Capocaccia; Otto Visser; Rafael Marcos-Gragera; Marc Maynadié; Arianna Simonetti; Jean-Michel Lutz; Franco Berrino
Journal:  Blood       Date:  2010-07-27       Impact factor: 22.113

7.  The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene.

Authors:  I S Lossos; T Akasaka; J A Martinez-Climent; R Siebert; R Levy
Journal:  Leukemia       Date:  2003-07       Impact factor: 11.528

8.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.

Authors:  Heike Horn; Marita Ziepert; Claudia Becher; Thomas F E Barth; Heinz-Wolfram Bernd; Alfred C Feller; Wolfram Klapper; Michael Hummel; Harald Stein; Martin-Leo Hansmann; Christopher Schmelter; Peter Möller; Sergio Cogliatti; Michael Pfreundschuh; Norbert Schmitz; Lorenz Trümper; Reiner Siebert; Markus Loeffler; Andreas Rosenwald; German Ott
Journal:  Blood       Date:  2013-01-18       Impact factor: 22.113

9.  Preclinical validation of fluorescence in situ hybridization assays for clinical practice.

Authors:  Anne E Wiktor; Daniel L Van Dyke; Peggy J Stupca; Rhett P Ketterling; Erik C Thorland; Brandon M Shearer; Stephanie R Fink; Kimberly J Stockero; Jason R Majorowicz; Gordon W Dewald
Journal:  Genet Med       Date:  2006-01       Impact factor: 8.822

10.  Quality assessment of HER2 testing by monitoring of positivity rates.

Authors:  Harald Choritz; Guntram Büsche; Hans Kreipe
Journal:  Virchows Arch       Date:  2011-08-02       Impact factor: 4.064

View more
  1 in total

1.  Numerical and structural genomic aberrations are reliably detectable in tissue microarrays of formalin-fixed paraffin-embedded tumor samples by fluorescence in-situ hybridization.

Authors:  Heike Horn; Julia Bausinger; Annette M Staiger; Maximilian Sohn; Christopher Schmelter; Kim Gruber; Claudia Kalla; M Michaela Ott; Andreas Rosenwald; German Ott
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.